[ad_1]
The vaccine that the North American Pfizer developed with the German company BioNTech showed a success rate of 95%, in its latest test of its effectiveness in preventing coronavirus, the American pharmaceutical company has just announced.
The company also revealed that it has already registered the necessary safety data to submit the application for approval to the Food and Drug Administration – the regulatory authority – so it will proceed with an emergency request for approval in the coming days.
“The test results mark an important step in this historic eight-month journey to present a vaccine that can help end this devastating pandemic,” said Albert Bourla, CEO of Pfizer in the statement. He adds that “we continue to advance at the speed of science to collect all the data acquired so far and share it with regulators around the world.”
Ugur Sahin, CEO of BioNTech, highlights that the success achieved “highlights the importance of RNA, as a new class of antidotes. “This vaccine was designed based on RNA – ribonucleic acid, which results from the transcription of a sequence of genetic material – using inactive parts of the virus to stimulate immunity in the bodies.
It is the first time in history that a vaccine manufactured with this methodology has the authorization of the regulators, should it occur.
The American pharmacist, a BioNTech partner, shows that its vaccine is effective in people of all ages and ethnicities, without compromising its safety in tests that were carried out on a sample of about 44,000 participants.
The new efficacy rate is higher than the 90% recorded during preliminary testing last week and slightly exceeds the 94.5% success rate shown by the Modern counterpart vaccine. In the coming days, the results of the vaccine from the British AstraZeneca and the University of Oxford are also expected to be published.
The effectiveness of the Pfizer-BioNTech vaccine in people over 65 years of age is 94%, highlights the pharmaceutical company, showing that only 3.7% of the total sample revealed fatigue after the second dose – when necessary -, but the company notes that it was the only recorded side effect.
Following the new announcement, Pfizer shares rose 2.7% in the session leading up to Wednesday’s opening on Wall Street, while BioNTech soared more than 7%.
[ad_2]
